Literature DB >> 26829408

Low Fecal Calprotectin Correlates with Histological Remission and Mucosal Healing in Ulcerative Colitis and Colonic Crohn's Disease.

Eran Zittan1, Orlaith B Kelly, Richard Kirsch, Raquel Milgrom, Jane Burns, Geoffrey C Nguyen, Ken Croitoru, Gert Van Assche, Mark S Silverberg, A Hillary Steinhart.   

Abstract

BACKGROUND: Data regarding the correlation of histologic and endoscopic healing with fecal calprotectin (FC) are conflicting. We examined how FC levels correlate with histological and endoscopic remission in colonic inflammatory bowel disease.
METHODS: Fifty-eight patients (23 with colonic Crohn's disease [CD] and 35 with ulcerative colitis [UC]) were included. Clinical activity was assessed by Harvey-Bradshaw index (CD) and Mayo score (UC). Inflammatory activity was assessed by ileocolonoscopy, C-reactive protein, and FC. Clinical remission was defined as Harvey-Bradshaw index ≤ 4 or Mayo score ≤ 2 and mucosal healing as Mayo endoscopic subscore = 0 (UC), and Simple Endoscopic Score-CD <3 (CD). Histologic activity was assessed in 27 patients (15 CD, 12 UC). Histological remission was defined as absence of active inflammation (Geboes score <3.1) and absence of basal plasmacytosis.
RESULTS: In UC, FC correlated with clinical Mayo score (r = 0.63, P < 0.0001). This correlation was strengthened by adding the endoscopic subscore (r = 0.90, P < 0.0001). The endoscopic subscore also independently correlated with FC (r = 0.96, P < 0.0001). In Crohn's colitis, endoscopic activity correlated with FC (r = 0.61, P < 0.001). FC levels were lower overall for patients with endoscopic remission compared with active endoscopic disease (median 100 versus 1180 μg/g, P < 0.0001). FC also correlated with histological remission (Geboes score < 3.1) and absence of basal plasmacytosis in CD (r = 0.77, r = 0.80, respectively; P < 0.01). Area under the curve for FC as a predictor of histological remission (Geboes score <3.1) was 0.95 (95% CI, 0.82-1).
CONCLUSIONS: Low FC correlates well with histological remission and mucosal healing in colonic inflammatory bowel disease and is thus a clinically useful surrogate for inflammatory activity.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26829408     DOI: 10.1097/MIB.0000000000000652

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  42 in total

1.  Response to Levenstein and Prantera.

Authors:  David J Gracie; Christopher J M Williams; Ruchit Sood; Saqib Mumtaz; M Hassan Bholah; P John Hamlin; Alexander C Ford
Journal:  Am J Gastroenterol       Date:  2016-10       Impact factor: 10.864

2.  Complete histologic normalisation is associated with reduced risk of relapse among patients with ulcerative colitis in complete endoscopic remission.

Authors:  Kelly C Cushing; William Tan; David H Alpers; Vikram Deshpande; Ashwin N Ananthakrishnan
Journal:  Aliment Pharmacol Ther       Date:  2019-11-07       Impact factor: 8.171

3.  Fecal Calprotectin in Assessing Endoscopic and Histological Remission in Patients with Ulcerative Colitis.

Authors:  Wing Yan Mak; Anthony Buisson; Michael J Andersen; Donald Lei; Joel Pekow; Russell D Cohen; Stacy A Kahn; Bruno Pereira; David T Rubin
Journal:  Dig Dis Sci       Date:  2018-02-22       Impact factor: 3.199

4.  Influence of Diet on the Course of Inflammatory Bowel Disease.

Authors:  Laura Tasson; Cristina Canova; Maria Grazia Vettorato; Edoardo Savarino; Renzo Zanotti
Journal:  Dig Dis Sci       Date:  2017-05-26       Impact factor: 3.199

Review 5.  Can faecal calprotectin predict relapse in inflammatory bowel disease: a mini review.

Authors:  T S Chew; J C Mansfield
Journal:  Frontline Gastroenterol       Date:  2016-04-05

6.  Clinical significance of fecal calprotectin for the early diagnosis of abdominal type of Henoch-Schonlein purpura in children.

Authors:  Xu Teng; Cuiyun Gao; Mei Sun; Jie Wu
Journal:  Clin Rheumatol       Date:  2017-10-10       Impact factor: 2.980

7.  First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: A 2020 Delphi consensus.

Authors:  Maryam Alkhatry; Ahmad Al-Rifai; Vito Annese; Filippos Georgopoulos; Ahmad N Jazzar; Ahmed M Khassouan; Zaher Koutoubi; Rahul Nathwani; Mazen S Taha; Jimmy K Limdi
Journal:  World J Gastroenterol       Date:  2020-11-21       Impact factor: 5.742

8.  Prognostic value of histological activity in patients with ulcerative colitis in deep remission: A prospective multicenter study.

Authors:  Triana Lobatón; Talat Bessissow; Alexandra Ruiz-Cerulla; Gert De Hertogh; Raf Bisschops; Jordi Guardiola; Gert Van Assche; Severine Vermeire; Marc Ferrante
Journal:  United European Gastroenterol J       Date:  2018-01-08       Impact factor: 4.623

9.  Developing a Neural Network Model for a Non-invasive Prediction of Histologic Activity in Inflammatory Bowel Diseases.

Authors:  Iolanda Valentina Popa; Mircea Diculescu; Catalina Mihai; Cristina Cijevschi Prelipcean; Alexandru Burlacu
Journal:  Turk J Gastroenterol       Date:  2021-03       Impact factor: 1.852

Review 10.  Faecal Calprotectin in Assessment of Mucosal Healing in Adults with Inflammatory Bowel Disease: A Meta-Analysis.

Authors:  Mariusz A Bromke; Katarzyna Neubauer; Radosław Kempiński; Małgorzata Krzystek-Korpacka
Journal:  J Clin Med       Date:  2021-05-19       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.